Oxford Gene Technology: Mike Evans. Providers of innovative genetics research and biomarker solutions to advance molecular medicine




Episode Loading...




PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Oxford Gene Technology: Mike Evans. Providers of innovative genetics research and biomarker solutions to advance molecular medicine
Released on: July 03, 2013. © PharmaTelevision Ltd
Share/save this page:
Email
Bookmark
Facebook
Twitter
LinkedIn
Follow us:
RSS
Twitter
In This Episode:
    Mike Evans, CEO of Oxford Gene Technology talks to Fintan Walton about OGT's new diagnostic techiques and innovative research into Lupus, Prostate and Colorectal cancers.
  • Summary
  • Transcript
  • Participants
  • Company
Mike Evans, CEO of Oxford Gene Technology talks to Fintan Walton about OGT's new diagnostic techiques and innovative research into Lupus, Prostate and Colorectal cancers.
Mike Evans, CEO of Oxford Gene Technology talks to Fintan Walton about OGT's new diagnostic techiques and innovative research into Lupus, Prostate and Colorectal cancers.
Mike Evans
Oxford Gene Technology
Oxford Gene Technology
Founded by Professor Ed Southern, Oxford Gene Technology (OGT) is focused on providing innovative genetics research and biomarker solutions to advance molecular medicine. The company has three core commercial arms: Genomics, Biomarkers and Licensing. In addition, an Exploratory Research division, headed by Professor Southern, focuses on developing new diagnostic techniques with potential for in-house commercialisation or partnering with diagnostic and pharmaceutical organisations. With its clear strategic focus, OGT has invested significantly in highly qualified expertise, doubling the workforce over the last 2 years to over 60 people. In anticipation of this rapid expansion, OGT moved to a new, purpose-built facility located in the Begbroke Science Park near Oxford, UK. These strategic decisions have resulted in strong year-on-year revenue growth across all business units. The company plans further expansion fuelled by growth into the clinical research market, a full pipeline of new products and further corporate development opportunities. OGT’s highly experienced management team are driving this growth through end-user sales and by forging strong relationships with major international corporations including Agilent, Illumina and Roche.